Granisetron Hydrochloride
A hydrochloride salt form of granisetron, a 5-HT3 antagonist antiemetic used to prevent and treat nausea and vomiting associated with chemotherapy and postoperative settings. The hydrochloride salt form is used in both oral tablets and injectable preparations. It provides effective antiemetic coverage, particularly for acute chemotherapy-induced nausea occurring within the first 24 hours of treatment.
Molecular Weight
348.9000 g/mol
TPSA
50.20 Ų
Therapeutic Areas
Mechanism of Action
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D Structure
Cite this structure
Embed this structure
SMILES
CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2.Cl
InChI
InChI=1S/C18H24N4O.ClH/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17;/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23);1H
Molecular Formula
C18H25ClN4O
HBD / HBA
2 / 3
Rotatable Bonds
2
Heavy Atoms
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A hydrochloride salt form of granisetron, a 5-HT3 antagonist antiemetic used to prevent and treat nausea and vomiting associated with chemotherapy and postoperative settings. The hydrochloride salt form is used in both oral tablets and injectable preparations. It provides effective antiemetic coverage, particularly for acute chemotherapy-induced nausea occurring within the first 24 hours of treatment.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Granisetron Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237080. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 65264. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="granisetron-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/granisetron-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/granisetron-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/granisetron-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="granisetron-hydrochloride"></drugfyi-drug>